RESUMO
Intrauterine adhesions (IUAs) can lead to partial or complete closure of the uterine cavity, which may result in symptoms including abnormal menstruation, infertility, and pelvic pain. A network meta-analysis was performed to assess the effect of adjuvant therapy on the prevention and treatment of IUAs. We searched electronic databases, including PubMed, Embase, and the Cochrane Library, up to May 5, 2017, without language restrictions. The primary outcomes in the present analysis were the rate of IUAs for prevention and the rate of IUA recurrence for treatment. The secondary outcomes included the IUA score and the rate of severity of IUAs. The treatments were then ranked by the surface under the cumulative ranking curve (SUCRA). We included 20 articles that involved a total of 1891 patients in our analysis. In the outcomes of prevention-related studies, an alginate hyaluronate-carboxymethylcellulose membrane (ACH) (n = 10, SUCRA score = 93.3%) was the adjuvant treatment that most effectively reduced IUA incidence. It was followed by intercoat (n = 10, SUCRA score = 74.7%) and misoprostol (n = 10, SUCRA score = 68.6%). In addition, auto-cross-linked hyaluronic acid (ACP) (n = 3, SUCRA score = 83.2%) and intercoat (n = 3, SUCRA score = 66.4%) each corresponded to a relatively high preventive effect against severe IUAs. In the treatment-related studies, ACP plus a balloon (n = 4, SUCRA score = 96.3%) and a freeze-dried amnion graft plus a balloon (n = 4, SUCRA score = 62.7%) most effectively reduced IUA recurrence and had a high probability of most effectively reducing IUA scores. Therefore, according to the prophylactic analysis, ACH and intercoat were most likely to prevent IUA development. In our analysis of agents used to prevent severe IUAs, we found that ACP and intercoat provided significant advantages and had high reliability. In our analysis of treatments, ACP plus a balloon and freeze-dried amniotic agents plus a balloon were most likely to reduce IUA recurrence and IUA scores after adhesiolysis.
Assuntos
Ginatresia/prevenção & controle , Aderências Teciduais/prevenção & controle , Doenças Uterinas/prevenção & controle , Alginatos/uso terapêutico , Âmnio/transplante , Celulase/uso terapêutico , Terapia Combinada , Feminino , Humanos , Ácido Hialurônico/uso terapêutico , Terapia Neoadjuvante , Metanálise em Rede , Ensaios Clínicos Controlados Aleatórios como Assunto , Recidiva , Reprodutibilidade dos Testes , Aderências Teciduais/etiologia , Doenças Uterinas/etiologiaRESUMO
Two cases of a chemical dissolution of gastric phytobezoars are presented. The novel approach of that management is the pharmacological mixture than completely made disappear the bezoars in patients fated to surgery removal.
Assuntos
Bezoares/tratamento farmacológico , Bebidas Gaseificadas , Celulase/uso terapêutico , Fármacos Gastrointestinais/uso terapêutico , Pancreatina/uso terapêutico , Gastropatias/tratamento farmacológico , Ácido Ursodesoxicólico/uso terapêutico , Quimioterapia Combinada , Humanos , Resultado do TratamentoRESUMO
Subcellular components of the probiotics Aeromonas sobria GC2 and Bacillus subtilis JB-1, when administered to rainbow trout, Oncorhynchus mykiss, conferred protection against a new biogroup of Yersinia ruckeri. Thus, intraperitoneal or intramuscular injection of rainbow trout with cell wall proteins (CWPs), outer membrane proteins (OMPs), lipopolysaccharides (LPS), whole cell proteins (WCPs) and live cells followed by challenge on day 8 with Y. ruckeri led to 80-100% survival compared with 10% survival in the controls. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) profiles of WCPs and OMPs from GC2 had 10 and 5 variable protein bands in comparison to 11 and 5 bands in the WCPs and CWPs from JB-1. Proteomic analyses were employed following SDS-PAGE to categorize one dominant protein of 104.7 kDa from the CWPs of JB-1 and equated it with 'Bacillus spp. endoglucanase' with a Mascot score >69. These results point to the potential of using cellular components of probiotics for protection of fish against bacterial diseases.
Assuntos
Celulase/uso terapêutico , Doenças dos Peixes/prevenção & controle , Oncorhynchus mykiss/imunologia , Probióticos/uso terapêutico , Yersiniose/veterinária , Yersinia ruckeri , Aeromonas , Animais , Bacillus , Proteínas de Bactérias/metabolismo , Proteínas de Bactérias/uso terapêutico , Celulase/metabolismo , Doenças dos Peixes/imunologia , Doenças dos Peixes/microbiologia , Oncorhynchus mykiss/microbiologia , Frações Subcelulares/metabolismo , Yersiniose/imunologia , Yersiniose/microbiologia , Yersiniose/prevenção & controleRESUMO
OBJECTIVE: To determine if a hyaluronic acid/carboxymethylcellulose (HA/CMC) sinus dressing reduces the rate of postoperative scarring. METHODS: In a randomized, matched-controlled, single-blinded study, following the completion of surgery, an HA/CMC dressing was randomly assigned to one side with the opposite unpacked side serving as a control. RESULTS: Fifty-three patients underwent surgery for chronic rhinosinusitis (CRS; 39 patients) or CRS with nasal polyposis (14 patients). At the 8-week follow-up, there was no difference in synechiae on the HA/CMC side compared to the control (p = 0.09). HA/CMC-treated sinuses, however, demonstrated fewer synechiae in the first 2 weeks postoperatively compared to the control (p = 0.01), and were associated with significantly less nasal congestion at the 4-week (p = 0.02) and 8-week follow-up visits (0.03). CONCLUSION: There was no long-term difference in the rate of synechiae in the HA/CMC-treated sinus compared to the control. However, less severe nasal congestion and synechiae in the initial postoperative period may reduce the need for aggressive sinus debridement.
Assuntos
Bandagens , Celulase/uso terapêutico , Endoscopia , Ácido Hialurônico/uso terapêutico , Complicações Pós-Operatórias/prevenção & controle , Sinusite/cirurgia , Adulto , Idoso , Idoso de 80 Anos ou mais , Doença Crônica , Desbridamento , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Cavidade Nasal , Estudos Prospectivos , Resultado do Tratamento , Adulto JovemRESUMO
INTRODUCTION: A bezoar is a hard mass of undigested foreign matter found in the gastrointestinal system. The most common type is the phytobezoar, which is composed of vegetable fibres. There is no current consensus as to its treatment. Three cases of phytobezoars treated with cellulase are described. PATIENTS AND METHOD: Case 1: patient with large gastric phytobezoar. Initial treatment with nasogastric cola drink lavages was ineffective. Subsequent treatment with cellulase was successful. Case 2: patient with gastric phytobezoar who was treated with cellulase and metoclopramide. Definitive fragmentation was performed with the endoscopy technique. Case 3: patient with large intestinal phytobezoar. The patient was treated by endoscopic lysis with partial success. Subsequent treatment with cellulase led to complete disintegration. In all the cases, cellulase was administered in pure form by nasogastric tube, and none of the patients suffered adverse effects. CONCLUSIONS: Treatment with cellulase is based on the enzymatic degradation of the bezoar. It has been shown to be effective as the treatment of choice in earlier studies with few patients. This agent seems to be a good alternative for patients with large phytobezoars.
Assuntos
Bezoares/tratamento farmacológico , Celulase/uso terapêutico , Idoso , Idoso de 80 Anos ou mais , Bezoares/patologia , Feminino , Humanos , MasculinoRESUMO
A review of phytobezoars is presented, emphasizing medical treatment using enzymatic dissolution for bezoar located in the gastric pouch. Clinical and in vitro studies show the efficacy of both papain and cellulase, and it is suggested that, since each acts on a different component of the bezoar, they be administered in combination. There were no complications with this treatment in the patients reported in this series.
Assuntos
Bezoares/tratamento farmacológico , Terapia Enzimática , Plantas Comestíveis , Celulase/uso terapêutico , Quimioterapia Combinada , Humanos , Íleo , Enteropatias/tratamento farmacológico , Papaína/uso terapêutico , Pepsina A/uso terapêutico , Gastropatias/tratamento farmacológicoRESUMO
The plant fiber content (cellulose, hemicellulose, lignin, and tannins) in phytobezoars was determined. Phytobezoars were found to have a high concentration of polymerized tannins composed mainly of leucoanthocyanins and catechins. Unripe fruit was found to have a high concentration of the tannin monomers. It is concluded that the formation of phytobezoars is due to the polymerization of these tannin monomers. On the ingestion of unripe fruit, the hydrochloric acid of the stomach initiates the polymerization, resulting in a tannin-cellulose-hemicellulose-protein complex. This complex disintegrated in a crude preparation of cellulase. Cellulase is a simple and effective method of treating human gastric phytobezoars.
Assuntos
Bezoares/etiologia , Celulase/uso terapêutico , Frutas/efeitos adversos , Bezoares/tratamento farmacológico , Celulose/análise , Cromatografia em Camada Fina/métodos , Frutas/análise , Humanos , Lignina/análise , Taninos/análise , Fatores de TempoRESUMO
BACKGROUND: The aim of our study was to analyze the efficacy of cellulase in dissolving gastric phytobezoars. METHODS: We carried out a prospective study over a period of 1 year. All patients (7 cases) diagnosed as having gastric phytobezoar on gastroscopy were treated with cellulase. RESULTS: Complete dissolution of the gastric phytobezoar was achieved in all 7 patients. No side effects or recurrences occurred during follow-up. DISCUSSION: We conclude that cellulase should be regarded as the treatment of choice for gastric phytobezoars because of its efficacy, and because of the lack of side effects or recurrences. However, further clinical trials are necessary to verify these findings.
Assuntos
Bezoares/tratamento farmacológico , Celulase/uso terapêutico , Estômago , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos ProspectivosRESUMO
No disponible
Assuntos
Humanos , Bezoares/tratamento farmacológico , Celulase/uso terapêutico , Pancreatina/uso terapêutico , Ácido Ursodesoxicólico/uso terapêutico , Bebidas Gaseificadas , Resultado do TratamentoRESUMO
No disponible
Assuntos
Humanos , Masculino , Pessoa de Meia-Idade , Obstrução Intestinal/etiologia , Bezoares/complicações , Acloridria/complicações , Motilidade Gastrointestinal , Fatores de Risco , Celulase/uso terapêuticoRESUMO
PURPOSE: To describe a patient with a history of epithelial basement membrane dystrophy who developed symptomatic corneal verticillata after vandetanib therapy for anaplastic astrocytoma. METHODS: Retrospective interventional case report. RESULTS: A 48-year-old female patient with a history of anaplastic astrocytoma status post resection, external beam radiation, and chemotherapy presented with glare symptoms, decreased contrast sensitivity, and increased lacrimation after approximately 12 months of therapy with the anti-epidermal growth factor receptor (EGFR) and anti-vascular endothelial growth factor receptor 2 protein tyrosine kinase inhibitor, vandetanib. Ophthalmic examination revealed diffuse corneal verticillata and fine subepithelial opacities. Schirmer 1 testing was normal bilaterally. Therapy with carboxymethylcellulose, 5% sodium chloride ointment, and a decrease in the dose of vandetanib led to an improvement in the patient's ophthalmic symptoms despite persistence of the corneal findings. The patient remained under surveillance for tumor recurrence. CONCLUSIONS: Vandetanib (ZD6474), a protein tyrosine kinase inhibitor with dual anti-EGFR and anti-vascular endothelial growth factor receptor 2 action, may have contributed to the formation of corneal verticillata in our patient. Inhibition of EGFR, which is involved with corneal epithelial cell migration and wound healing, may play a role in the pathogenesis underlying corneal vortex keratopathy and ocular surface conditions with significant epithelial turnover.
Assuntos
Astrocitoma/tratamento farmacológico , Neoplasias Encefálicas/tratamento farmacológico , Doenças da Córnea/induzido quimicamente , Receptores ErbB/antagonistas & inibidores , Recidiva Local de Neoplasia/tratamento farmacológico , Piperidinas/efeitos adversos , Quinazolinas/efeitos adversos , Receptor 2 de Fatores de Crescimento do Endotélio Vascular/antagonistas & inibidores , Astrocitoma/cirurgia , Neoplasias Encefálicas/cirurgia , Celulase/uso terapêutico , Doenças da Córnea/patologia , Opacidade da Córnea/induzido quimicamente , Relação Dose-Resposta a Droga , Esquema de Medicação , Quimioterapia Combinada , Feminino , Humanos , Pessoa de Meia-Idade , Pomadas , Piperidinas/administração & dosagem , Quinazolinas/administração & dosagem , Estudos Retrospectivos , Cloreto de Sódio/uso terapêuticoRESUMO
No disponible
Assuntos
Humanos , Bezoares/tratamento farmacológico , Celulase/uso terapêutico , Fibras na Dieta/efeitos adversosAssuntos
Bezoares/tratamento farmacológico , Celulase/uso terapêutico , Adulto , Idoso , Celulase/administração & dosagem , Celulase/efeitos adversos , Celulose/química , Celulose/metabolismo , Fibras na Dieta/efeitos adversos , Endoscopia , Feminino , Humanos , Enteropatias/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Gastropatias/tratamento farmacológicoRESUMO
Phytobezoars are plant fibre concretions occurring in the stomach as a complication following some types of gastric surgery. Symptoms include distension, pain and vomiting. Ulceration, gastric bleeding and even perforation can occur. If untreated, they result in a significant mortality. Dissolution of the phytobezoar can be achieved without operative intervention. Enzymes and especially cellulase help to break up the mass and it can then be aspirated or allowed to pass on. Five patients with phytobezoars were thus treated and the cellulase method was confirmed to be simple, safe and effective.
Assuntos
Bezoares/tratamento farmacológico , Celulase/uso terapêutico , Plantas , Adulto , Idoso , Bezoares/etiologia , Gastrectomia , Humanos , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias , Fatores de TempoRESUMO
The purpose of this review article is to provide the clinician with complete information concerning available medicinal agents for the management of phytobezoars. Data sources were obtained by a Medline search from 1966 to present. All citations containing references to patients with a phytobezoar treated with medicinal agents were selected and reviewed for treatment regimen, number of patients treated, length of therapy, success rate, and adverse effects. A total of 36 patients with phytobezoars were reviewed. Papain was successful in treating 87% (13 of 15) and cellulase in 100% (19 of 19) of the patients. Adverse effects reported in the papain group were gastric ulcer, esophageal perforation, and hypernatremia; the cellulase group did not report any adverse effects. Papain and cellulase appeared to be effective in the management of phytobezoars in the small number of patients studied. However, controlled clinical trials are needed to compare the safety and efficacy of the two agents.